# Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

> **NCT02922166** · PHASE1 · UNKNOWN · sponsor: **Azevan Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Fear
- Anxiety

## Interventions

- **DRUG:** SRX246
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02922166
- **Lead sponsor:** Azevan Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-03
- **Primary completion:** 2019-05-10
- **Final completion:** 2019-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02922166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02922166, "Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02922166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*